Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. 1986

J Goldfarb, and G P Wormser, and M A Inchiosa, and G Guideri, and M Diaz, and R Gandhi, and C Goltzman, and A V Mascia

The single-dose pharmacokinetics of oral ciprofloxacin were studied in ten patients with cystic fibrosis aged 18 to 34 years. Each patient received three different drug doses (500 mg, 750 mg, and 1,000 mg) at successive one-week intervals. Dosing and drug assays were double blinded. Blood and urine were assayed over the 48 hours following each dose. Ciprofloxacin was absorbed from the gastrointestinal tract. Peak serum concentrations averaged 2.8, 4.5, and 4.6 micrograms/mL respectively at the three doses, well above the mean inhibitory concentrations of most isolates of Pseudomonas aeruginosa. Time to peak concentration was approximately two hours. The range of sputum levels in three patients was 1.1-2.1 micrograms/mL at four hours after the three doses. The serum elimination half-life was 3.7 hours and was independent of dose. Urinary recovery was 26%; greater than 90% of urinary excretion occurred within the first 12 hours. The results of this study indicate that ciprofloxacin has potential for use in the treatment of P aeruginosa infections in patients with cystic fibrosis.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D011804 Quinolines
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

J Goldfarb, and G P Wormser, and M A Inchiosa, and G Guideri, and M Diaz, and R Gandhi, and C Goltzman, and A V Mascia
January 1986, Infection,
J Goldfarb, and G P Wormser, and M A Inchiosa, and G Guideri, and M Diaz, and R Gandhi, and C Goltzman, and A V Mascia
May 1984, Antimicrobial agents and chemotherapy,
J Goldfarb, and G P Wormser, and M A Inchiosa, and G Guideri, and M Diaz, and R Gandhi, and C Goltzman, and A V Mascia
January 2001, Therapie,
J Goldfarb, and G P Wormser, and M A Inchiosa, and G Guideri, and M Diaz, and R Gandhi, and C Goltzman, and A V Mascia
January 1996, Antimicrobial agents and chemotherapy,
J Goldfarb, and G P Wormser, and M A Inchiosa, and G Guideri, and M Diaz, and R Gandhi, and C Goltzman, and A V Mascia
June 1987, Antimicrobial agents and chemotherapy,
J Goldfarb, and G P Wormser, and M A Inchiosa, and G Guideri, and M Diaz, and R Gandhi, and C Goltzman, and A V Mascia
June 1988, International journal of clinical pharmacology, therapy, and toxicology,
J Goldfarb, and G P Wormser, and M A Inchiosa, and G Guideri, and M Diaz, and R Gandhi, and C Goltzman, and A V Mascia
August 1986, Antimicrobial agents and chemotherapy,
J Goldfarb, and G P Wormser, and M A Inchiosa, and G Guideri, and M Diaz, and R Gandhi, and C Goltzman, and A V Mascia
October 1986, Antimicrobial agents and chemotherapy,
J Goldfarb, and G P Wormser, and M A Inchiosa, and G Guideri, and M Diaz, and R Gandhi, and C Goltzman, and A V Mascia
January 1986, Pediatric pulmonology,
J Goldfarb, and G P Wormser, and M A Inchiosa, and G Guideri, and M Diaz, and R Gandhi, and C Goltzman, and A V Mascia
November 2012, Journal of clinical pharmacology,
Copied contents to your clipboard!